Lynparza for gliomas – pro
Glioblastoma (GBM) remains a life-limiting disease with a median overall survival of 14.6 months.vOlaparib monotherapy appeared well-tolerated and demonstrated evidence of antitumor activity among patients with heavily pretreated isocitrate dehydrogenase-mutant high-grade glioma, and it penetratesthes cacners and potentiates the effect of radiation. A recent review by SIM concluded that currently, there are limitations with the available clinical trial data, principally due to the heterogeneity in the study populations, variety of treatment regimens, early phase uncontrolled designs and small patient numbers. These make it difficult to draw strong conclusions at this time. There is interesting research but not yet conclusive evidence that lYnparza is useful for gliomas.
Hao-Wen Sim et al, PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities. Cancers 2022, 14, 1003.
Marina Kushnirsky, Andrew Lin, Alexandra Miller, Igor Gavrilovic, Craig Nolan, Elena Pentsova, Ingo Mellinghoff, Thomas Kaley, Lauren Schaff, Concurrent Olaparib and Temozolomide for Recurrent Glioma (P5-9.005)
Neurology May 2022, 98 (18 Supplement) 2219;
Hanna C, Kurian KM, Williams K, Watts C, Jackson A, Carruthers R, Strathdee K, Cruickshank G, Dunn L, Erridge S, Godfrey L, Jefferies S, McBain C, Sleigh R, McCormick A, Pittman M, Halford S, Chalmers AJ. Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial. Neuro Oncol. 2020 Dec 18;22(12):1840-1850